© 2012

Thyroid Cancer

  • Glenn D. Braunstein

Part of the Endocrine Updates book series (ENDO, volume 32)

Table of contents

  1. Front Matter
    Pages i-x
  2. Gretchen E. Galliano, David P. Frishberg
    Pages 1-33
  3. Wenwen Chien, H. Phillip Koeffler
    Pages 35-43
  4. Glenn D. Braunstein, Wendy Sacks
    Pages 45-61
  5. Michelle Melany
    Pages 63-91
  6. Shikha Bose
    Pages 93-108
  7. Ronnie Meiyi Wong, Glenn D. Braunstein
    Pages 109-131
  8. Wendy Sacks, Glenn D. Braunstein
    Pages 133-153
  9. Jerome Hershman, Adam Lyko
    Pages 155-169
  10. Nicole M. Tyer, Run Yu
    Pages 171-187
  11. Marina Vaysburd
    Pages 189-199
  12. Basil Rapoport, Sandra M. McLachlan
    Pages 201-205
  13. C. Suzanne Cutter, Kenneth W. Adashek, Michel Babajanian, Babak Larian
    Pages 207-241
  14. Wendy Sacks, Alan D. Waxman
    Pages 243-270
  15. Stephen W. Lim
    Pages 301-315
  16. Back Matter
    Pages 317-322

About this book


The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women.  The overall 5-year survival rate is about 97%, making it one of the least lethal cancers.  We are experiencing an epidemic of well-differentiated thyroid cancer, in part due to the widespread use of imaging modalities that detect thyroid nodules and microcarcinomas. Concurrently, there have been a number of recent advances in surgical treatment, as well as diagnostic modalities that allow us to detect small amounts of residual local and metastatic disease. Additionally, a reexamination of past treatment regimens has led to new recommendations regarding the use of radioactive iodine, and to new therapeutic options, such as targeted therapy which have supplanted the use of more toxic chemotherapy for metastatic cancer.  Multiple academic organizations have developed consensus guidelines for the management of thyroid cancer, occasionally with conflicting recommendations. In  Thyroid Cancer, a renowned group of authors presents  a broad overview of the pathology, pathophysiology, diagnosis, and management of thyroid cancer, with an emphasis on recent evidence-based information. State-of-the-art and a significant contribution to the literature, Thyroid Cancer is an invaluable reference for endocrinologists, oncologists, nuclear medicine physicians, radiation oncologists, primary care physicians, and surgeons who deal with head and neck cancer.


Cancer Carcinoma Fine Needle Aspiration Nodules Thyroid

Editors and affiliations

  • Glenn D. Braunstein
    • 1
  1. 1.Department of Medicine, The James R. Klinenberg M.D. Chair in MeProfessor and Chairman,Los AngelesUSA

Bibliographic information

  • Book Title Thyroid Cancer
  • Editors Glenn D. Braunstein
  • Series Title Endocrine Updates
  • Series Abbreviated Title Endocrine Updates
  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Springer, Boston, MA
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-1-4614-0874-1
  • Softcover ISBN 978-1-4899-7798-4
  • eBook ISBN 978-1-4614-0875-8
  • Series ISSN 1566-0729
  • Edition Number 1
  • Number of Pages X, 322
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Internal Medicine
  • Buy this book on publisher's site


From the reviews:

“The book is appropriate for practitioners involved in the care of patients with thyroid cancer, including internists, endocrinologists, surgeons, oncologists, radiologists, radiation oncologists, and pathologists. Students and housestaff officers with a particular interest in thyroid cancer also may find this book useful. … This is a comprehensive book on thyroid cancer with short and succinct chapters, making it very readable. It will be of interest to those who want to learn more about advances in thyroid cancer diagnosis and management.” (Rebecca L. Brown, Doody’s Review Service, March, 2012)